<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The distinction between mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) and other low-grade B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> is important because <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> has a more aggressive clinical course </plain></SENT>
<SENT sid="1" pm="."><plain>In bone marrow biopsy specimens, this distinction can be especially difficult </plain></SENT>
<SENT sid="2" pm="."><plain>We examined 70 bone marrow biopsy specimens involved by various B-cell lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> to assess the utility of cyclin D1 immunostaining in distinguishing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> from other B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We used a cocktail of two monoclonal anti-cyclin D1 antibodies and a heat- and sonication-induced <z:chebi fb="0" ids="53000">epitope</z:chebi> retrieval procedure </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:hpo ids='HP_0002664'>neoplasms</z:hpo> assessed included <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (32 cases), small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (18 cases), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (11 cases), hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (5 cases), splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (2 cases), and small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with plasmacytoid differentiation (2 cases) </plain></SENT>
<SENT sid="5" pm="."><plain>The diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> in bone marrow was confirmed by review of the original diagnostic biopsy specimens along with additional data, such as immunophenotypic or molecular studies </plain></SENT>
<SENT sid="6" pm="."><plain>Most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> (23/32; 72%) cases expressed cyclin D1 protein </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, one case of small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (1/18; 6%) and one case of hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1/5; 20%) expressed cyclin D1 protein </plain></SENT>
<SENT sid="8" pm="."><plain>These findings demonstrate that immunostaining for cyclin D1 protein expression is useful in distinguishing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> from other B-cell lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in the bone marrow </plain></SENT>
</text></document>